Patent Rebuff For Roche’s Valcyte In India, Again
Executive Summary
Roche’s powder formulation for Valcyte (valganciclovir) has failed to secure a patent in India, at least for now, with the patent office seeing no ‘technical advancement’ in the invention.
You may also be interested in...
Medicines Patent Pool Takes Novel Approach With Roche In Valcyte Deal
Roche and the Medicines Patent Pool have signed a five-year deal that will allow developing countries to achieve faster access to the Swiss company’s CMV drug, Valcyte for 90% less.
India dismisses patent on Roche's Valcyte
India has set aside a patent on Roche's Valcyte (valganciclovir) used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.